Author: Fiona Craig

Oxford Biomedica (LSE:OXB) said it has strengthened its long-standing collaboration with Bristol Myers Squibb after signing a new multi-year commercial supply agreement covering the manufacture of lentiviral vectors for BMS’s CAR-T cell therapy programmes. The agreement runs for an initial five-year term, with an option to extend, and represents a shift from clinical-stage support to commercial-scale manufacturing.

Under the terms of the deal, Oxford Biomedica expects to begin commercial production in 2026 at its facilities in Oxford in the UK and Durham, North Carolina, subject to regulatory approvals. The company said the contract is expected to deliver meaningful revenue over multiple years and provides greater confidence around its medium-term financial guidance. Management highlighted the agreement as validation of its focused CDMO strategy, improving revenue visibility while reinforcing its position as a key supplier of high-quality viral vectors as demand for scalable CAR-T manufacturing continues to grow.

Despite the strategic significance of the deal, Oxford Biomedica’s broader outlook remains constrained by financial pressures, including ongoing losses, negative cash flows and elevated leverage, even as recent revenue growth has been strong. From a market perspective, technical indicators remain supportive, with the share price in a clear uptrend and a positive MACD signal, although very elevated RSI and stochastic readings point to increased near-term pullback risk. Valuation continues to be limited by negative earnings and the absence of a dividend yield.

More about Oxford Biomedica

Oxford Biomedica is a global contract development and manufacturing organisation specialising in cell and gene therapies. With around three decades of experience in viral vectors, the company develops and manufactures lentiviral, AAV, adenoviral and other vectors for pharmaceutical and biotechnology partners, supporting programmes from early development through to commercial supply. The FTSE 250-listed group is headquartered in Oxford, UK, with development and manufacturing sites in the UK, France and the United States, and a portfolio of proprietary technologies including its fourth-generation TetraVecta lentiviral vector system.

Eco Buildings Group plc (LSE:ECOB) said it has launched a philanthropic initiative to donate a complete modular hospital building system for a new community hospital in Malicounda, Senegal. The project will use the company’s proprietary low-carbon construction technology and will be delivered alongside an existing public school developed under the same municipal partnership, enabling rapid deployment of the healthcare facility.

The hospital will be delivered in collaboration with Spanish non-governmental organisation Amigos de Buba, which will fund and manage transport and installation, while local joint-venture partner G2 Invest will oversee site preparation and coordination with municipal authorities. Eco Buildings said the donation will not impact its current contracts or revenue forecasts, but will serve as a strategic reference project to demonstrate the flexibility of its modular systems in healthcare settings.

Management views the Senegal installation as a way to strengthen relationships with governments, NGOs and development partners, particularly across West Africa, and to highlight the applicability of its modular technology in emerging markets. From a market perspective, Eco Buildings’ outlook continues to be supported by positive corporate developments that point to potential growth opportunities, even as financial performance and valuation remain challenging. Technical indicators suggest a mixed picture, with longer-term trends supportive but some near-term uncertainty still evident.

More about Eco Buildings Group plc

Eco Buildings Group plc is a UK-listed sustainable construction company specialising in prefabricated modular building systems made from large glass fibre reinforced gypsum panels. The group focuses on delivering cost-efficient, rapid and low-carbon construction solutions for housing and public infrastructure projects in international markets, particularly where scalable, factory-built technologies are in demand.

GlobalData Plc (LSE:DATA) said it is planning to move its stock market listing from AIM to the Main Market of the London Stock Exchange, with the intention of admitting its entire issued ordinary share capital to the FCA’s Official List in the Equity Shares (Commercial Companies) category. The company expects the transfer to complete on 5 March 2026 through an introduction of existing shares, alongside the cancellation of its AIM quotation, subject to the necessary regulatory approvals.

Management said the move is designed to elevate GlobalData’s profile by positioning the group on a more established and liquid trading venue, which could improve visibility with institutional investors and help broaden the shareholder base. The transition comes alongside a period of strong financial performance and strategic corporate actions, including share buyback activity, which have been viewed positively by the market.

At the same time, technical indicators point to bearish momentum in the share price, and valuation remains a point of debate, with a relatively high price-to-earnings ratio raising questions around potential overvaluation. Taken together, the outlook reflects a balance between GlobalData’s solid fundamentals and strategic progress, and near-term market and valuation risks.

More about GlobalData Plc

GlobalData Plc is a London-listed provider of industry intelligence, supplying data, analytics and insights to corporate and financial clients across a wide range of sectors. The company focuses on delivering decision-support information that helps customers assess markets, competitors and industry trends.

Banco Santander S.A. (LSE:SAN) said it has filed a comprehensive set of documents relating to its 2025 financial results, providing detailed disclosure of the group’s performance over the year. The materials include the full annual financial report, earnings presentations and additional supporting information intended to give investors and regulators a clear view of recent trading and strategic developments.

The documents have been submitted to the UK’s National Storage Mechanism and are now available for public inspection. Management said the disclosures are expected to play a role in shaping market analysis of the bank’s financial position, operating momentum and progress against its longer-term strategic objectives.

More about Banco Santander S.A.

Banco Santander S.A. is an international banking and financial services group headquartered in Spain. The group provides retail and commercial banking, corporate and investment banking, wealth management and a wide range of related financial products to individuals, businesses and institutional clients across Europe, the Americas and other major global markets.

Gem Diamonds Limited (LSE:GEMD) said its fourth-quarter 2025 performance met or exceeded revised operational targets, even as full-year production volumes declined. During the quarter, the company recovered 90,354 carats at an average price of US$1,288 per carat, helping to support cash preservation efforts amid a challenging operating environment.

Management said disciplined cost controls played a key role in the quarter, with measures such as deferred waste stripping keeping both direct and operating costs toward the lower end of guidance. However, this approach led to higher waste unit costs. Sales of several notable high-value diamonds during the period, along with the recovery of a 193-carat stone shortly after quarter end, highlighted the continued premium nature of production from the Letšeng mine and its ability to underpin revenue resilience.

From a broader perspective, Gem Diamonds’ outlook is increasingly supported by improving financial performance, with profitability turning positive and free cash flow showing a strong recovery alongside a stable leverage position. These positives are tempered by weaker technical signals, as the share price remains below major moving averages and the MACD indicator is negative. In addition, management commentary has pointed to near-term operational pressures, including negative EBITDA, a year-on-year revenue decline and impairment charges, despite ongoing cost initiatives and available liquidity.

More about Gem Diamonds Limited

Gem Diamonds Limited is a UK-listed diamond mining company focused on the production of high-value rough diamonds from its majority-owned Letšeng mine in Lesotho. The operation is known for yielding large, high-quality white diamonds that consistently achieve premium prices on a per-carat basis.

Cobra Resources plc (LSE:COBR) reported encouraging metallurgical test work from the Head Prospect, located on newly acquired tenements close to its flagship Boland Project in South Australia. The results indicate that rare earth mineralisation hosted within the Pidinga Formation could be suitable for scalable, low-cost in-situ recovery, particularly for heavy rare earth elements.

The company said diagnostic leach testing on historical composite samples from the Head Prospect delivered recoveries of around 50% for key rare earth elements and materially outperformed samples taken from underlying saprolite and weathered granite. These outcomes have reinforced Cobra’s view that the large 85 square kilometre palaeochannel system has the potential to significantly expand the project’s resource base and strengthen the overall economic rationale for ISR-based development. Step-out and resource-focused drilling is scheduled to begin in March 2026, with the aim of identifying thick, ISR-recoverable mineralised zones and building sufficient scale to support a maiden mineral resource estimate.

From an investment perspective, Cobra’s outlook continues to be weighed down by its financial profile, with no revenue generation, ongoing losses and sustained cash burn, although this is partly offset by the absence of debt on the balance sheet. Technical indicators remain a clear positive, with the share price trading above major moving averages and supported by healthy momentum. Valuation remains difficult to assess, however, due to negative earnings and the lack of dividend yield information.

More about Cobra Resources plc

Cobra Resources plc is a London-listed exploration and development company focused on advancing a potentially large-scale ionic rare earth element discovery at its Boland Project in South Australia. The company is targeting high-value heavy and magnet rare earths, including terbium and dysprosium, within permeable palaeochannel systems that are considered suitable for low-cost, low-impact in-situ recovery, positioning Cobra as a potential supplier of critical rare earths outside China.

Andrada Mining Limited (LSE:ATM) said it has met the final two conditions required to unlock an initial US$10 million investment from BWCAM for the Brandberg West project. The funding gives the ACAM affiliate a 30% interest in the project vehicle and allows work to accelerate on tailings investigations, although approval from the Namibian Competition Commission is still pending.

In addition to the project-level investment, BWCAM has subscribed a further US$1 million for 24.3 million new Andrada shares at a price of 3p each. Admission of the new shares to AIM is expected on 9 February, strengthening Andrada’s balance sheet and reinforcing the strategic partnership as the company continues to expand its exploration and production activities across Namibia.

Despite solid revenue growth, Andrada’s overall outlook remains constrained by financial pressures, including ongoing losses, negative return on equity, and negative operating and free cash flow. From a market perspective, the share price trend remains supportive, with a clear upward trajectory, although elevated momentum indicators suggest an increased risk of short-term pullbacks. Valuation remains limited by a negative price-to-earnings ratio and the absence of dividend yield guidance.

More about Andrada Mining Limited

Andrada Mining Limited is an AIM-listed mining company focused on Namibia, producing tin while expanding into lithium, tantalum, tungsten and copper. Through strategic partnerships, the group aims to supply critical minerals that support the global energy transition.

Atlas Metals Group plc (LSE:AMG) said it has put in place a £10 million at-the-market equity facility with Axis Capital Markets to strengthen its funding position as it advances the proposed reverse takeover of Universal Pozzolanic Silica Alumina. The facility is intended to provide working capital, settle legacy creditor positions and cover transaction-related costs, with Axis also appointed as joint broker. Atlas has issued an initial 720,820 new shares under the arrangement.

In parallel, the company confirmed that warrant exercises and loan note conversions will result in the issue of a further 4.3 million shares. Once all 5,017,321 new shares are admitted to trading on 5 February, Atlas’s total voting share capital is expected to rise to around 29.1 million shares. While the enlarged share base represents modest dilution for existing shareholders, management said the added flexibility improves the group’s ability to fund the UPSA transaction as it moves forward.

The broader investment outlook for Atlas continues to be shaped by its financial profile, with negligible revenue, ongoing losses, negative equity and continued cash burn weighing on sentiment. Technical indicators offer only limited short-term support and remain weak over longer timeframes, while valuation metrics are constrained by the company’s loss-making status and the absence of dividend yield visibility.

More about Atlas Metals Group plc

Atlas Metals Group plc is a London-listed natural resources and energy company focused on the acquisition and development of mineral assets. Its current strategic priority is the proposed purchase of Universal Pozzolanic Silica Alumina, which would broaden the group’s exposure to industrial minerals.

Cizzle Biotechnology Holdings PLC (LSE:CIZ) said it has secured patent approval in Canada for its CIZ1B biomarker, strengthening protection for its proprietary two-step blood test for the early detection of lung cancer. The newly granted patent enhances the commercial position of its licensing partner, Cizzle Bio Inc, as rollout efforts continue across North America, while also supporting the company’s wider strategy to build a globally protected intellectual property portfolio alongside anticipated U.S. approvals.

The reinforced patent coverage underpins Cizzle’s ambition to align its technology with national early-detection frameworks, including the NHS cancer plan, and is intended to support deeper engagement with clinical laboratories and hospital networks. Management said the expanded intellectual property footprint is central to safeguarding shareholder value by ensuring exclusive use of the CIZ1B technology as commercial partnerships scale in key markets.

Despite the strategic progress on intellectual property, the company’s overall outlook remains constrained by financial factors. Cizzle continues to operate on a pre-revenue basis, with ongoing losses, sustained cash outflows and a significantly reduced equity base weighing on sentiment. Technical indicators also suggest muted share price momentum, while valuation metrics offer limited support due to negative earnings and the absence of dividend visibility.

More about Cizzle Biotechnology Holdings PLC

Cizzle Biotechnology Holdings PLC is a biotechnology company focused on the development of non-invasive, blood-based diagnostics for the early detection of lung cancer. Its work centres on the CIZ1B biomarker, with the technology licensed to partners across North America, the Caribbean and other regions, while the group also targets expansion aligned with NHS initiatives in the UK and Europe.